PRED FORTE Rx
Generic Name and Formulations:
Prednisolone acetate 1%; oph. susp; contains benzalkonium chloride, sulfites.
Indications for PRED FORTE:
Adults and Children:
Instill 1–2 drops 2–4 times daily. During the initial 24–48hrs, the dosing frequency may be increased if needed.
Fungal, mycobacterial, viral (except herpes zoster) or untreated bacterial infections.
Corneal or scleral thinning. Glaucoma. Myopia. Diabetes. Asthma. Monitor for secondary infections and intraocular pressure in prolonged use. May mask or exacerbate infections. Avoid abrupt cessation. Re-evaluate if no improvement after 2 days. Pregnancy. Nursing mothers.
Increased intraocular pressure, posterior subcapsular cataract formation, delayed wound healing, corneal perforations, optic nerve damage, defects in visual acuity and fields of vision, allergic reactions, dysgeusia, eye pain, foreign body sensation, headache, others.
Mild—5mL, 10mL; Forte—5mL, 10mL, 15mL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML